Free tool
FAERS Monitor: Phesgo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761170 or its brand name (Phesgo, Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf). Reports on generic versions are filed under their own applications.
Reports
4,830
Serious
1,826
38% of reports
Hospitalization
625
Death reported
292
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event912
- off label use902
- diarrhoea432
- injection site pain213
- pain212
- death164
- fatigue163
- injection site reaction162
- pyrexia157
- disease progression142
- rash140
- asthenia137
- nausea114
- malaise112
- vomiting99
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 5 |
| 2021 | 51 |
| 2022 | 195 |
| 2023 | 388 |
| 2024 | 2,853 |
| 2025 | 763 |
| 2026 | 575 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,329 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| no adverse eventSignal | 912 | 22.0 | 20.8 | 18,349 |
| injection site reactionSignal | 162 | 10.3 | 8.8 | 1,348 |
| disease progressionSignal | 142 | 5.2 | 4.4 | 484 |
| off label useSignal | 902 | 4.5 | 4.2 | 2,546 |
| injection site painSignal | 213 | 3.0 | 2.7 | 291 |
| diarrhoeaSignal | 432 | 2.9 | 2.7 | 559 |
| pyrexia | 157 | 2.0 | 1.7 | 76 |
| asthenia | 137 | 1.6 | 1.3 | 30 |
| pain | 212 | 1.5 | 1.3 | 36 |
| rash | 140 | 1.4 | 1.2 | 16 |
| malaise | 112 | 1.1 | 0.9 | 1 |
| vomiting | 99 | 0.9 | 0.8 | 1 |
| fatigue | 163 | 0.9 | 0.8 | 1 |
| death | 164 | 0.8 | 0.7 | 6 |
| nausea | 114 | 0.6 | 0.5 | 26 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.